Trial Profile
Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination With the Histone Deacetylase Inhibitor Entinostat in Patients With Metastatic Renal Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Aug 2023
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Entinostat (Primary) ; Fludeoxyglucose F-18
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 02 Aug 2023 Planned End Date changed from 17 Jul 2023 to 17 Jul 2024.
- 02 Aug 2023 Planned End Date changed from 17 Jul 2023 to 17 Jul 2024.
- 06 May 2019 Planned primary completion date changed from 23 Feb 2019 to 23 Jun 2019.